Liquid Biopsy Market
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong><br />
Share, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation and Forecast,<br />
2016<br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports and country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive and Transportation<br />
• Electronics, Semiconductor, and ICT<br />
• Retail and Consumer Products<br />
• Industrial Automation and Equipment<br />
• Chemicals & Materials<br />
• Food and Beverages<br />
• Services and Utilities<br />
• Energy, Mining, Oil, and Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
<strong>Liquid</strong> biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies.<br />
<strong>Liquid</strong> biopsy helps in collection of a wide range of information about a cancer/tumor<br />
through a simple blood sample. The procedure can help in exact detection of mutations<br />
in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC).<br />
Furthermore, identification of traces of the cancer’s DNA in the blood could help in<br />
administration of precision treatments that could increase the probability of treatment<br />
effectiveness. <strong>Liquid</strong> biopsies are also helpful in residual cancer detection. This minimally<br />
invasive method can be performed with 5 milliliters of blood which would detect present<br />
state of metastases in various tumors. The liquid biopsy process is witnessing increasing<br />
adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is<br />
expected to emerge as a game changer in the field of oncology in the forthcoming years.<br />
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong>: Drivers and Restraints<br />
Foremost drivers for the liquid biopsy market include. Factors such as tolerability and<br />
patient convenience are promoting adoption of liquid biopsies. <strong>Liquid</strong> biopsy procedures<br />
are replacing tissue diagnosis procedures which often is not possible through tissue<br />
biopsy in cases of non-small cell lung cancers. Clinical trial conducted by the companies<br />
have been noted that the liquid biopsies could also help in detection of cancer in its early<br />
stage of than arrival of particular symptoms. This could lead to provision of a longer<br />
treatment horizon and better chances of elongating the survival period of the patient.<br />
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1396
Report Description<br />
Lack of documented evidence about the efficacy of the process, cost-intensive nature of<br />
the research process that leads to frequent clinical trial abandonment and dearth of<br />
people with specialized knowledge on the same are the factor hindering the growth of<br />
liquid biopsy market. Countries with limited capital investment in R&D infrastructure and<br />
dearth of skilled professionals, would largely influences the development pace of the<br />
technology and thus its establishment as a preferred biopsy method.<br />
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong>: Segmentation<br />
Biosimilars and Follow-on Biologics <strong>Market</strong> can be segmented into these following ways:<br />
• Segmentation by approach of diagnosis<br />
• Circulating Tumor Cells (CTC)<br />
• Circulating Tumor DNA (ctDNA)<br />
• RNA in exosomes<br />
• Extra-cellular vesicles (EVs)<br />
• Segmentation by type of cancer application<br />
• Lung cancer<br />
• Pancreatic cancer<br />
• Leukemia<br />
• Other visceral (deeply located) cancers
Report Description<br />
•Segmentation by channel participants<br />
• Cancer Centers and Hospitals<br />
• Contract Research Organizations<br />
• Academic Institutions<br />
• Specialized research laboratories<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1396<br />
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong>: Overview<br />
The revolutionary nature of liquid biopsy procedure is expected to create noise in the<br />
field of tissue biopsy and innovative cancer diagnosis in near future. Large drug makers<br />
are increasing entering into collaborative partnerships with leading academic institutions<br />
such as Dana Farber Cancer Research Institute, University of Oxford, U.S. National Cancer<br />
Institute, and others to increase the rapidity of research in liquid biopsy. The current<br />
prospect of the market is however limited to developed countries in the world but is<br />
expected to exhibit significantly high CAGR over a ten-year forecast period.<br />
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong>: Region-wise Outlook<br />
Depending on geographic regions, liquid biopsy market is segmented into seven key<br />
regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific,<br />
Japan, and Middle East & Africa. All major action in the field of liquid biopsy is expected<br />
to emerge from North America and Europe region over the forecast period.
Report Description<br />
However, with development of sophisticated R&D infrastructure in emerging region such<br />
as APAC, is expected to gain traction supported through gradual availability of low-cost<br />
meaningful liquid biopsy option in cancer diagnosis. Other factors expected to prominent<br />
impact on the growth of liquid biopsy are increasing patient awareness and affordability<br />
levels & regulatory harmonization. However, increasing funding for private public<br />
partnerships in field of cancer research is expected to fuel the adoption of liquid biopsy<br />
over the forecast period. Moreover, the rising disease incidence of lung and pancreatic<br />
cancer in all major regions of the world is expected to drive the growth of liquid biopsy<br />
market.<br />
Browse full report: http://www.futuremarketinsights.com/reports/liquid-biopsy-market<br />
<strong>Liquid</strong> <strong>Biopsy</strong> <strong>Market</strong>: Key Players<br />
Some of the key players in the liquid biopsy market are Janssen Diagnostics, Qiagen,<br />
Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal<br />
Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome<br />
Sciences, and HansaBiomed OU among others.
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
For other queries contact: Mr. Sudip Saha<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language